Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Big Drugmakers That May Tread the M&A Path After Pfizer

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

Pfizer (PFE) Gains But Lags Market: What You Should Know

Pfizer (PFE) closed at $43.08 in the latest trading session, marking a +0.45% move from the prior day.

Protalix (PLX) Completes Enrollment in Fabry Disease Study

Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.

Sweta Killa headshot

Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio

Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.

Company News For Jun 18, 2019

Companies In The News Are: DISH,TMUS,S,ARRY,PFE,BID,BA

Big Ticket Mergers Are in Focus

Big Ticket Mergers Are in Focus

Mark Vickery headshot

"Merger Monday" Returns: Pfizer Buying Array, T-Mobile-Sprint on Ice?

News on two major mergers in their respective industries are taking headlines, along with a fresh regional economic read.

Swarup Gupta headshot

Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout

The index traversed a volatile week, guided largely by trade-related developments.

Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti

FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.

Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study

Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.

Galapagos Ends Enrollment in Osteoarthritis Study Before Time

Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.

Novartis Reports Data on Cosentyx for Psoriatic Arthritis

Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.

Pfizer (PFE) Gains As Market Dips: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $43.10, marking a +1.01% move from the previous day.

Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer

Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.

Kinjel Shah headshot

Boost Your Portfolio's Health With These 3 Big Drug Stocks

The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

Top Ranked Income Stocks to Buy for June 12th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 12th

TherapeuticsMD Enters Agreement to Market Drugs Outside US

TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $42.76, marking a +0.66% move from the previous day.

Lilly's Emgality Gets FDA Approval for Cluster Headache

Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.

Zacks Market Edge Highlights: Pfizer, Vanguard S&P 500 ETF, Global X Social Media ETF, Kraneshares China Internet ETF and Microsoft

Zacks Market Edge Highlights: Pfizer, Vanguard S&P 500 ETF, Global X Social Media ETF, Kraneshares China Internet ETF and Microsoft

Blueprint Medicines to File NDA for Avapritinib With FDA

Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.

Tracey Ryniec headshot

Top Tips for Long-Term Stock Investors

The stock market is volatile again. Here's how to make it through the ups and downs.

The Zacks Analyst Blog Highlights: Pfizer, Coca-Cola, VMware, NIKE and AIG

The Zacks Analyst Blog Highlights: Pfizer, Coca-Cola, VMware, NIKE and AIG

Pfizer to Launch Several Drugs Despite Generic Headwinds

Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.